Dr. Seyoung Jang
Dr. Edward Turos
TSC MEMBER INSTITUTION(S):
University of South Florida
National Institutes of Health
National Science Foundation
NANOPHARMA TECHNOLOGIES, INC.
ABOUT THE COMPANY:
Nanopharma Technologies, Inc., a “spin-out” company at the University of South Florida (USF), got its start in 2004 when it won two federal Small Business Technology Transfer (STTR) grants for development of anti-anthrax antibiotics and drug-delivery platforms. The platforms were discovered by USF Chemistry professor Edward Turos, founder and scientific director of the company.
In 2004, the Turos research group announced that it had active scientific collaborations around the world., including at the USF Center for Biological Defense, the USF Medical School, and the H. Lee Moffitt Cancer Center. “USF is a perfect place for us to do this kind of work,” said co-founder Dr. Seyoung Jang. “We are grateful for the university’s commitment to provide a nourishing atmosphere for new businesses like ours.”
Nanopharma is currently researching and developing new antibiotics and biomaterials to treat and prevent drug-resistant hospital infections. In addition, the company is developing anti-bioterrorism agents against anthrax and is seeking new anticancer therapies. The cancer therapies include designing nano-sized vehicles — one billion times smaller than the head of a pin — to provide improved antibiotics passage to infection sites.
UNIVERSITY-BASED RESEARCH CONNECTION:
Dr. Edward Turos is co-founder and Chief Scientific Advisor to the company. He is a Full Professor at the Department of Chemistry at the University of South Florida.
ROLE OF FEDERAL RESEARCH FUNDING:
“Antibacterially-Active Nanoparticles” was funded by the National Science Foundation. “A Mechanically Novel Antibiotic for Anthrax” was funded by the National Institutes of Health.
Read The Full Report Here